Showing results (101-110 of 149) with videos related to
Sort By:
Pageof 15
Internal Medicine (Tokyo, Japan)|July 20, 1999
Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNAY Arase, K Ikeda, K Chayama, et al.The American Journal of Gastroenterology|November 24, 1999
Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatitis BY Arase, K Ikeda, N Murashima, et al.Hepatology (Baltimore, Md.)|March 30, 1999
Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysisK Ikeda, S Saitoh, Y Arase, et al.Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|March 1, 1997
[Cranial MRI in the patients with chronic liver disease (CLD)]T Nakamura, S Saitoh, K Ikeda, et al.Journal of Gastroenterology and Hepatology|January 26, 1999
Relationship of angiographic finding with neovascular structure detected by immunohistochemical staining of alpha-smooth muscle actin in small hepatocellular carcinomaK Ikeda, S Saitoh, Y Suzuki, et al.Intervirology|October 25, 2000
Relationship between five-year histological outcome and serial changes in serum alanine aminotransferase in patients with biochemical and virological relapse after interferon treatment for chronic hepatitis CM Kobayashi, K Ikeda, N Akuta, et al.Journal of Gastroenterology|March 3, 2001
Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutantT Someya, Y Suzuki, Y Arase, et al.Journal of Gastroenterology|April 28, 2001
Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimenF Suzuki, K Chayama, A Tsubota, et al.Journal of Medical Virology|November 26, 1998
Deletions in the hepatitis B virus core gene may influence the clinical outcome in hepatitis B e antigen-positive asymptomatic healthy carriersA Tsubota, H Kumada, K Takaki, et al.Cancer|March 5, 1998
Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot studyK Ikeda, S Saitoh, Y Suzuki, et al.Pageof 15